Gilead Sciences (GILD) shares oversold argues BofA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BofA Securities Upgrades Gilead Sciences (GILD) to Buy on HIV drug upside
September 8, 2023 6:05 AM EDT(Updated - September 8, 2023 6:40 AM EDT)
BofA Securities analyst Geoff Meacham upgraded Gilead Sciences (NASDAQ: GILD) from Neutral to Buy with a price target of $95.00 (from $88.00).
The analyst commented "We are upgrading GILD shares to Buy (from Neutral) and raising our PO to... More
Gilead Sciences (GILD) Prices $2B Notes Offering
September 8, 2023 5:46 AM EDTGilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $2 billion, in an underwritten, registered public offering, consisting of $1... More
Amgen and Biogen 'look attractive' - HSBC
September 6, 2023 11:39 AM EDTHSBC initiated coverage of 11 US biopharmaceutical and healthcare stocks in a note to clients on Wednesday.
Analyst Morten Herholdt assigned Actinium Pharma (NYSE: ATNM), Amgen (NASDAQ: AMGN), Biogen (NASDAQ: BIIB), Bluebird... More
HSBC Starts Gilead Sciences (GILD) at Reduce
September 6, 2023 3:14 AM EDTHSBC analyst Morten Herholdt initiates coverage on Gilead Sciences (NASDAQ: GILD) with a Reduce rating and a price target of $71.00.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $75.16 yesterday.
... More